The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

Ozempic, Wegovy or Mounjaro: the battle of the weight-loss injections - As weight-loss injections emerge as key players in ...

FDA has not approved any generic versions of semaglutide." Eli Lilly, makers of Mounjaro and Zepbound, also used for weight loss, told CBS News: "Lilly has taken steps to help inform people about the ...

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...

A turbulent series of events surrounding the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around how the Food and Drug Administration maintains its list of drug ...

Oct 21 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its ...

Eli Lilly has suffered a major setback after the US regulator rejected its rheumatoid arthritis pill, baricitinib, sending the company’s share price plummeting. Lilly received a letter from the ...

Lilly may have suffered a major disappointment ... selling injected drug Humira (adalimumab), and in a more convenient pill form. Olumiant, developed in partnership with US biotech Incyte, is ...

VK2735, which is being developed in both as an injectable and in pill form, is most closely related to Lilly's Zepbound (tirzepatide), given that both are dual GLP-1/GIP agonist. The oral form of ...